Follow
Cancer Diagnostics
Cancer diagnostics often begin with a biopsy and histopathologic examination, from the basis of physical examination and medical history. Sometimes the first indication is an abnormal laboratory test result (eg, anemia resulting from colon cancer).
MAY 31, 2023 | 11:00 AM
Date: May 31, 2023 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CET) Single-cell genomics has facilitated the understanding of mechanisms involved in various biological processes such as tumor...
MAY 17, 2023 | 10:00 AM
C.E. CREDITS
Participate in this educational webinar to learn about key objects in Treponemal screening. Today's presentation will cover the following topics from the perspective of a NYC based Labor...
APR 25, 2023 | 10:00 AM
C.E. CREDITS
Date: April 25, 2023 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) A liquid biopsy is a non-invasive alternative to a surgical biopsy that enables researchers to learn a range of infor...
APR 19, 2023 | 10:00 AM
C.E. CREDITS
Date: April 18, 2023 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Whilst a decade ago the prognosis of lung cancer patients has been very disappointing, nowadays a substantial evolutio...
APR 05, 2023 | 5:30 AM
C.E. CREDITS
In search of the next generation chromatographic technique for antibody purification, our team has developed an affinity chromatography method using the unconventional nucleotide binding sit...
MAR 30, 2023 | 1:50 PM
C.E. CREDITS
Liquid biopsy tests are an integral part of the molecular diagnostic workup of cancer specimens. We have performed extensive validation studies of the GeneStrat NGS test (GSNGS), that uses a...
MAR 30, 2023 | 1:50 PM
Liquid biopsy tests are an integral part of the molecular diagnostic workup of cancer specimens. We have performed extensive validation studies of the GeneStrat NGS test (GSNGS), that uses a...
MAR 30, 2023 | 1:20 PM
C.E. CREDITS
...
MAR 30, 2023 | 12:05 PM
Dr. Ritterhouse's laboratory has implemented rapid and ultra rapid protocol for NSCLC genomic profiling, based on NGS. This has led to significant shortening of turn around time (TAT) an...
MAR 30, 2023 | 5:10 PM
This talk will highlight key changes to the various guidelines in myeloid and lymphoid testing, commenting on the current and future landscape of biomarkers. The speakers will then share the...
MAR 30, 2023 | 1:50 PM
C.E. CREDITS
Clinical laboratories worldwide are implementing various targeted panels to identify cancer genomic variants and ultimately improve patient outcomes. As most of the panels and NGS platforms...
MAR 30, 2023 | 1:50 PM
Clinical laboratories worldwide are implementing various targeted panels to identify cancer genomic variants and ultimately improve patient outcomes. As most of the panels and NGS platforms ...
